Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

Inclusion Criteria - Subject must be 18 or older and in good health - Subject must meet the definition of early rheumatoid arthritis (RA) defined by the 1987-revised American College of Rheumatology (ACR) classification criteria and had disease duration of less than 1 year from diagnosis - Subject must have a Disease Activity Score (DAS28, based on C-reactive protein) greater than 3.2, at least 6 swollen joints out of the 66 assessed, and at least 8 tender joints out of the 68 assessed - Subject must fulfill at least one of the following three criteria: - Rheumatoid factor positive - Greater than 1 joint erosion - Anti-cyclic citrullinated peptide (CCP) antibody positive. Exclusion Criteria - Subject has previously received systemic anti-tumor necrosis factor (TNF) therapy - Subject has received any biologic or investigational therapy within 6 weeks prior to Baseline - Subject has been previously treated with more than 2 disease-modifying antirheumatic drugs (DMARDs) or MTX, had been treated with intra-articular or parenteral administration of corticosteroids in preceding 4 weeks, or had undergone joint surgery within the preceding 2 months at joints to be assessed during the study.